ESMO Highlights: Promising data for the frontline treatment of gynecologic cancer
During the ESMO 2022, several new and exciting overall survival data were presented. In this MEDtalk, associate professor Kristina Lindemann, Department of gynecologic cancer and head of research group for gynecological oncology, Oslo University Hospital, gives her perspective on long-term OS results and frontline treatment of ovarian, cervical, and endometrial cancer with a focus on PARP- and immune checkpoint-inhibitor.
